Eczema Trial, Recruiting (NCT06627335)

Eczema Trial, Recruiting NCT06627335 Sponsor: Incyte Corporation Condition: Eczema

Printed from Voxsanity (voxsanity.com.au) — NCT06627335 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Eczema

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are a woman who was 14 years old or older at the time your pregnancy ended
Your pregnancy occurred after September 21, 2021 (the date a cream called ruxolitinib was approved by the FDA)
You have at least one pharmacy record showing you were dispensed either ruxolitinib cream or a topical corticosteroid (a type of skin cream/ointment used to treat skin conditions)
You had a diagnosis of a skin condition called atopic dermatitis (eczema) before or on the same day as your first prescription for one of these creams
You were continuously enrolled in the relevant health database from 6 months before your estimated conception date through to the end of your pregnancy
If the study is looking at outcomes for your baby, there must be a way to link your health records to your baby's health records — your baby's data will be followed for up to 1 year after birth, or for however long they remain enrolled in the database

Who may not be able to join:

You have pharmacy records showing you were prescribed ruxolitinib taken by mouth (as a pill or liquid), or any other similar medications called JAK inhibitors, during the relevant timeframe of the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Incyte Medical Monitor, Incyte Corporation

Phone: 1.855.463.3463

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06627335

Sponsor: Incyte Corporation

Phase: Not Applicable

Status: Recruiting

Condition: Eczema

Trial contact: 1.855.463.3463

More information: https://clinicaltrials.gov/study/NCT06627335

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are a woman who was 14 years old or older at the time your pregnancy ended
Your pregnancy occurred after September 21, 2021 (the date a cream called ruxolitinib was approved by the FDA)
You have at least one pharmacy record showing you were dispensed either ruxolitinib cream or a topical corticosteroid (a type of skin cream/ointment used to treat skin conditions)
You had a diagnosis of a skin condition called atopic dermatitis (eczema) before or on the same day as your first prescription for one of these creams
You were continuously enrolled in the relevant health database from 6 months before your estimated conception date through to the end of your pregnancy
If the study is looking at outcomes for your baby, there must be a way to link your health records to your baby's health records — your baby's data will be followed for up to 1 year after birth, or for however long they remain enrolled in the database

Who may not be able to join:

You have pharmacy records showing you were prescribed ruxolitinib taken by mouth (as a pill or liquid), or any other similar medications called JAK inhibitors, during the relevant timeframe of the study

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Incyte Corporation

Registry

ClinicalTrials.gov

Start date

27 March 2023

Est. completion

15 August 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of major congenital malformation (MCM)s

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov